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Abstract 237 words 
Aim: The study objective was to investigate whether small dense LDL cholesterol 
(sdLDL-C) was superior to LDL-C and other biomarkers to predict future 
cardiovascular events (CEs) in secondary prevention.  
Methods: sdLDL-C measured by a homogeneous assay, remnant lipoprotein 
cholesterol (RLP-C), LDL particle diameter (LDL-PD), and other biomarkers were 
compared in 345 men ≥65 years of age with stable coronary artery disease (CAD). 
Baseline LDL-C was 100.5 ± 30.1 mg/dL. CEs were CEs, including cardiovascular 
death, onset of acute coronary syndrome, need for arterial revascularization, 
hospitalization for heart failure, surgery procedure for cardiovascular disease, and 
hospitalization for stroke were monitored for 5 years. 
Results: CEs occurred in 96 patients during the study period. LDL-C, sdLDL-C, 
non-HDL-C, apolipoprotein B, RLP-C, glucose, HbA1c, and BNP were significantly 
higher; LDL-PD and apolipoprotein A-1 were significantly lower in patients with than 
in those without CEs. Age-adjusted Cox regression analysis showed that sdLDL-C per 
10 mg/dL but not LDL-C was significantly associated with CEs (HR 1.206, 95% CI 
1.006–1.446). A significant association of sdLDL-C and incident CEs was observed in 
statin users (HR 1.252, 95% CI 1.017–1.540), diabetes patients (HR 1.219, 95% CI 
1.018–1.460), patients without diabetes (HR 1.257, 95% CI 1.019–1.551), and 
hypertriglyceridemia (HR 1. 376, 95% CI 1.070–1.770). 
Conclusions: sdLDL-C was the most effective predictor of residual risk of future CEs 
in stable CAD patients using statins and in high-risk CAD patients with diabetes or 
hypertriglyceridemia. 
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INTRODUCTION 
Low-density lipoprotein cholesterol (LDL-C) is currently considered as the most 
important target for reducing cardiovascular risk. LDL includes fractions of large 
buoyant and small dense particles1). Small dense LDL (sdLDL) particles are thought to 
be more atherogenic than large buoyant LDL (lbLDL) because of higher penetration of 
the arterial wall, lower binding affinity for the LDL receptor, prolonged plasma half-life, 
and lower resistance to oxidative stress 1-3). Increased sdLDL cholesterol (sdLDL-C) 
represents an increase in the number of atherogenic LDL particles because sdLDL 
particles are smaller and contain less cholesterol. 
The HDL Atherosclerosis Treatment Study reported a positive association of the 
plasma concentration of sdLDL particles and progression of coronary artery stenosis 
that was confirmed by gradient gel electrophoresis (GGE), vertical auto profile 
ultracentrifugation, nuclear magnetic resonance spectroscopy, and ion mobility4). In our 
cross sectional studies, heparin magnesium precipitation was used to demonstrate that 
high sdLDL-C, not high lbLDL-C, concentration was closely associated with the 
angiographic and/or clinical severity of coronary artery disease (CAD) independent of 
classical coronary risk factors 5,6). Our previous cohort study found that increased 
sdLDL-C and the sdLDL-C/LDL-C ratio were significantly associated with an elevated 
risk of cardiovascular events (CEs) in patients with stable CAD7), and prospective 
population-based cohort studies in Japan and the USA reported that increased sdLDL-C 
was significantly associated with the incidence of CAD independent of LDL-C 8-10). 
A meta-analysis of 61 prospective cohort studies showed that age substantially 
attenuated the positive relationship between total cholesterol and CAD mortality11). The 
INTERHEART study, a worldwide case-control study including more than 25,000 
participants, found a significant decline in the odds ratio of myocardial infarction (MI) 
for each change of one standard deviation (SD) in total cholesterol, LDL-C, 
non-high-density lipoprotein cholesterol (non-HDL-C), and apolipoprotein B (apoB) 
with increase in age12). The association of sdLDL-C with the risk of CE recurrence in 
elderly patients with CAD has not been compared with that of LDL-C. The study aim 
was to determine whether sdLDL-C is a better predictor than LDL-C and/or other lipid 
biomarkers of future CEs in elderly patients with stable CAD. 
 
METHODS 
Study Patients  
This observational cohort study included of 345 consecutive male patients ≥65 years of 
age with angiographically confirmed CAD at Showa University Hospital between 
September 2003 and December 2011. At the time the study began enrolling patients, 
aggressive lipid-lowering treatment was not common in patients with CAD. Significant 
CAD was defined as a 50% or greater narrowing of the diameter of one or more 
coronary artery branch on an arteriogram, and/or a prior history of percutaneous 
coronary intervention (PCI), and/or coronary artery bypass surgery (CABG). The 
peripheral artery disease (PAD) was defined as the Ankle Brachial Index (ABI) of less 
than 0.90 using an oscillometric device (Form/ABI, Colin Company, Ltd., Komaki, 
Japan) and/or history of endovascular treatment. Patients with acute coronary syndrome 
(ACS), nephrotic syndrome, renal dysfunction (serum creatinine >1.5 mg/dL), severe 
hepatic disease, infectious disease, currently treated for malignancy, on hemodialysis, 
taking drugs for thyroid dysfunction, or with any other serious condition were excluded. 
Patients who could not be followed for 3 months after coronary angiography were also 
excluded. The institutional review board of Showa University approved the study 
protocol, which was registered at UMIN-CTR (UMIN000027504). The investigation 
conformed to the ethical principles of the Declaration of Helsinki, and informed consent 
was obtained from all subjects. 
Baseline Evaluation  
Fasting blood samples were obtained by venipuncture immediate before cardiac 
catheterization. The LDL particle diameter (LDL-PD) and serum lipid biomarkers, 
except sdLDL-C, were assayed within 3 days of sampling; unused samples were stored 
−80ºC. Of the 345 participants, 245 men had a past history of MI, 272 had previously 
undergone PCI and/or, CABG, 234 were taking lipid-lowering drugs, and 102 men 
experienced coronary revascularization because of coronary angiography findings. 
Hypertension was determined by the medical history or by a pressure above 140 mmHg 
systolic or 90 mmHg diastolic 13). Diabetes mellitus was defined as a fasting serum 
glucose value >126 mg/dL, glycated hemoglobin (Hb) A1c values estimated by 
(=1.019×HbA1c [Japan Diabetes Society] + 0.3) greater than 6.5%, and/ or the current 
use of medication for diabetes13). Dyslipidemia was defined as the current use of 
lipid-lowering medications and/or meeting the criteria of the Japan Atherosclerosis 
Society for fasting serum lipid levels, i.e., LDL-C ≥140 mg/dL, HDL-C <40 mg/dL, or 
TG ≥ 150 mg/dL 13). A serum creatinine–based estimate of glomerular filtration rate 
(eGFR) was calculated as follows: eGFR = 194 x Cr-1.094 x Age-0.287 (x0.739 for 
women)14). Body mass index (BMI) was calculated as weight (kilograms) divided by 
height (meters) squared. Patients with a reported smoking habit of at least one cigarette 
per day on admission were classified as current smokers. 
Definition of CEs  
In-hospital medical records were evaluated 60 months after the baseline blood screening. 
The endpoints were: (1) the onset date of the first CE; (2) the date of death; and (3) the 
date of the patient’s last visit to Showa University Hospital. CEs were defined as death 
caused by CVD, onset of ACS, need for coronary or other arterial revascularization 
including restenosis after PCI; hospitalization for heart failure; surgery for any CVD; 
and hospitalization for ischemic or hemorrhagic stroke. Coronary revascularization 
within 3 months was not considered a CE because at that time, unexpected and 
scheduled coronary revascularization could not be distinguished. 
Lipoprotein and Brain Natriuretic Peptide Assays and Inflammatory Markers 
Total cholesterol, triglycerides, HDL-C, HbA1c, apolipoproteins, and lipoprotein(a) 
were assayed by standard laboratory procedures. RLPs were isolated from serum by 
immunoaffinity mixed gels containing anti-apolipoprotein A1 (apoA1) and 
anti-apoB100 monoclonal antibodies (Japan Immunoresearch Laboratories, Takasaki, 
Japan). The cholesterol concentrations of the unbound fraction were measured as 
RLP-C15). Serum LDL-C was determined by a direct homogenous assay using 
detergents (LDL-EX, Denka Seiken, Tokyo, Japan). Serum samples were kept frozen at 
−80ºC until used for a direct homogenous assay for sdLDL-C as previously described 16). 
The LDL-C and sdLDL-C assay kits were provided by Denka Seiken. LbLDL-C was 
estimated by subtracting the sdLDL-C concentration from the LDL-C concentration. 
The sdLDL-C/LDL-C ratio was also calculated from direct measurements. lbLDL-C 
values estimated by this method have previously been correlated with values determined 
by ultracentrifugation16). Non-HDL-C was estimated by subtracting the HDL-C 
concentration from the total cholesterol concentration, and peak LDL-PD was 
determined by 2%–16% nondenatured polyacrylamide gel electrophoresis as described 
by Nichols, et al.17). High sensitivity C-reactive protein (hsCRP) was assayed by the 
Dade Behring BN method18). Plasma brain natriuretic peptide (BNP) was measured by 
radioimmunoassay. 
Statistical Analysis  
Statistical analysis was performed using the SPSS 23.0 software package (SAS Institute, 
Cary, NC, USA). The baseline characteristics of patients with or without CEs during 
follow-up were compared using Wilcoxon tests, because most of the variables did not 
have a Gaussian distribution. Categorical variables were compared by chi-square tests. 
Although this was a case-control study, cumulative incidence was estimated by the 
Kaplan–Meier method in patients stratified by the median sdLDL-C level. The date of 
the baseline lipid measurements was set as the landmark point from which 
cardiovascular outcomes were evaluated. Clinical data obtained from patients who were 
lost to follow-up were censored, and were used for the period for which follow-up was 
available. Age-adjusted Cox regression analysis of the patient variables was used to 
calculate hazard ratios (HRs) with corresponding 95% confidence intervals (CIs) of the 
risk of future CEs. Variables that differed significantly in patients with and without CEs 
were included in a multivariate analysis. All statistical analyses were two-tailed, and p < 
0.05 was considered statistically significant. 
Results 
Baseline Characteristics and CEs 
The 5-, 3-, and 1-year follow-up rates were 75.5%, 84.8%, and 94.6%, respectively, and 
first-time CEs were observed in 96 (27.8%) of the 345 patients (Supplementary Table 
1). Eleven patients died of CVD, (one of an acute MI, six of heart failure, and four of 
unknown cause). Eighty-five (24.6%) were hospitalized with nonfatal CVDs, 11 (3.2%) 
with ACS, 11 (3.2%) with congestive heart failure, and 14 (4.05%) with ischemic stroke. 
Forty-six (13.3%) underwent revascularization and three (0.9%) received endovascular 
treatment. No patients were hospitalized with hemorrhagic stroke. Comparison of the 
baseline characteristics of patients with and without CEs (Table 1) revealed a 
significantly higher prevalence of diabetes and PAD, greater need for coronary 
revascularization at baseline, and fewer statin uses among those who experienced a CE. 
A comparison of laboratory findings (Table 2) found that the mean LDL-C was about 
100 mg/dL that was lower than that in a previously studied cohort7). The sdLDL-C in 
patients treated with statins were significantly lower than those untreated with statins 
(26.1 ± 11.5 vs 31.5 ± 14.2, p=0.003). LDL-C, sdLDL-C, non-HDL-C, LDL/HDL-C 
ratio, apoB, RLP-C, glucose, HbA1c, and BNP were significantly higher, and LDL-PD 
and apoA-1 were significantly lower in patients with CEs. The differences in lbLDL-C, 
HDL-C, eGFR, and hsCRP in the two groups were not significant.  
 
Correlation of LDL-C and SdLDL-C and Patient Characteristics  
The Spearman rank-order correlation of LDL-C and sdLDL-C and patient 
characteristics are shown in the Supplementary Table 2. Although sdLDL-C is a part 
of LDL-C, sdLDL-C had stronger correlations with biomarkers of atherogenic 
dyslipidemia such as triglycerides and RLP-C than LDL-C. 
 
Kaplan–Meier Event-Free Survival Analysis and Cox Regression Analysis  
The Kaplan-Meier event-free survival curves among patients above or below the 
median levels for sdLDL-C in patients, diabetic patients and patients treated with statins 
are shown in Figure 1. Sixteen patients who died of causes other than CVD and without 
experiencing any nonfatal CEs, were treated as censored cases. Patients with sdLDL-C 
≥ 25mg/dL were significantly increased risk for CEs (log-rank 6.155, p=0.003). Similar 
results were observed in diabetic patients and patients treated with statins at baseline 
(log-rank 6.492, p=0.011 and log-rank 4.193, p=0.041, respectively). Age-adjusted Cox 
regression analysis (Table 3) revealed that increases in LDL-C, sdLDL-C, non-HDL-C, 
LDL-C/HDL-C, apoB, glucose, HbA1c, and BNP, and decreases in LDL-PD and 
apoA1 were significantly associated with an increased risk of CEs; RLP-C was not. 
Multivariate analysis showed that decreased LDL-PD and increased HbA1c were 
significantly associated with CEs (Table 3, Model 1). Both LDL-C and sdLDL-C had 
significant positive correlations with non-HDL-C and apoB, and we found a negative 
correlation between sdLDL-C and LDL-PD. When LDL-C, sdLDL-C, and apoA1 
among lipid markers were included in the multivariate model, sdLDL-C per 10 mg/dL 
was independently associated with the risk of CEs (HR 1.210, 95% CI 1.003–1.459) 
(Table 3, Model 2).  The age-adjusted Cox regression analysis conducted in the study 
subpopulations is summarized in Table 4. Significant associations of sdLDL-C and 
occurrence of CEs were observed in various patient populations including patients 
treated with statins, those with or without diabetes, or those with hypertriglyceridemia. 
Both LDL-C and sdLDL-C were significantly associated with CEs in diabetes patients, 
but the significance was lost following multivariate analysis. The HRs were 1.063 (95% 
CI 0.945–1.196) for LDL-C and 1.129 (95% CI 0.889–1.433) for sdLDL-C. 
Discussion  
To the best of our knowledge, this is the first study to report that elevated sdLDL-C 
(determined by an automated homogenous assay) was independently associated with 
CE recurrence in elderly patients with stable CAD. These results are consistent with our 
previous obtained in 190 patients with stable CAD using precipitation assay of 
sdLDL-C concentration7). In the previous study, Cox’s proportional hazard analysis 
failed to find an association of increased sdLDL-C with the risk of CEs 7). In this study, 
multivariate Cox regression analysis showed that decreased LDL-PD was significantly 
associated with the occurrence of CEs independent of LDL-C and sdLDL-C, which is 
evidence in support of sdLDL as atherogenic LDL particles. The measurement of 
LDL-PD by GGE requires a separation time of >24 hours, which makes it unsuitable for 
use in clinical practice. The direct homogenous assay for sdLDL-C does not require any 
pretreatment and can be performed with the chemistry auto analyzers routinely used in 
clinical laboratories19). The study found a significant association between sdLDL-C and 
the occurrence of CEs in the entire study population and in high-risk subpopulations 
including diabetes patients and those with hypertriglyceridemia. The results confirm 
that sdLDL-C, compared with LDL-C, was a more important biomarker for secondary 
prevention. 
A meta-analysis of eight randomized controlled statin trials, found that 
on-treatment levels of non-HDL-C were more strongly associated with the risk of major 
CEs than the levels of LDL-C and apoB among statin-treated patients 20. A study of 
recent ACS patients treated with statins reported that fasting triglycerides at the initial 
randomization predicted short- and long-term risk of major CEs21. Both publications 
suggest that the cholesterol content of triglyceride-rich lipoproteins poses a residual risk 
in patients receiving effective statin therapy. A correlation of RLP-C and sdLDL has 
also been shown22, and Kugiyama et al. demonstrated that patients in the highest RLP-C 
tertile (> 5.1 mg/dL) in a group of 135 CAD patients had a higher incidence of CAD 
events than those in the lowest tertile (≤ 3.3 mg/dL), even though their LDL-C levels 
were less than 100 mg/dL23. In a later study of 190 patients treated with statins after 
ACS, they found that a high RLP-C (≥ 5.4 mg/dl) was a significant risk of secondary 
events independent of conventional risk factors (HR 2.94; 95% CI: 1.40–6.18; p < 
0.01)24. This study, which compared LDL-C, sdLDL-C, RLP-C, non-HDL-C, and apoB 
in patients with stable CAD, found that only sdLDL-C was independently associated 
with CEs in patients treated with statins. A recent study of the LDL-C reduction 
achieved by statins with or without ezetimibe in patients with ACS found a greater 
reduction of sdLDL-C in patients with coronary plaque regression (measured by 
ultrasound) than in those with plaque progression25. The evidence from a variety of 
sources thus supports sdLDL-C as a promising biomarker of residual risk in patients 
currently treated with statins. 
The Japanese Elderly Diabetes Intervention Trial found a positive association of 
LDL-C with incident coronary events. Both HbA1c and non-HDL-C were positively 
associated with stroke26. Cox regression analysis found that in this study, LDL-C, 
sdLDL-C, apolipoprotein B, and HbA1c were significantly associated with CEs in 
diabetes patients, and the HR for sdLDL-C was slightly higher than those for LDL-C 
and apoB. However, the association between these lipid biomarkers and CEs was no 
longer significant in the multivariate analysis. Future studies in large populations are 
required to investigate lipid biomarkers in diabetes patients with CAD. On the other 
hand, the association of increased sdLDL-C and non-HDL-C, and decreased in LDL-PD 
with CEs in patients without diabetes are in agreement with results of the Multi-Ethnic 
Study of Atherosclerosis. That study reported significant associations of sdlDL-C and 
incident CAD in patients with normal fasting glucose, not in those with impaired fasting 
glucose or diabetes mellitus9. 
This study has several limitations including a small sample size and low 
follow-up rate. Secondly, the CEs included those related to unstable plaque as well as 
revascularization for restenosis after PCI, atherogenic cardiovascular diseases, and 
ischemic heart failure requiring hospitalization. It remains unclear whether elevated 
sdLDL-C are related to ischemic heart failure. In addition, hospitalization of heart 
failure might be due to non-atherosclerotic disease, although all patients in the present 
study had coronary atherosclerosis. Thirdly, the effects of lipid-lowering therapy and 
target levels of sdLDL-C could not be investigated. Fourthly, lipid-lowering treatment 
was not evaluated during follow-up. Fifthly, left ventricular ejection fraction, frailty, 
malnutrition, and anemia were not captured in the analysis. Future prospective studies 
should thus be conducted to evaluate these issues in larger samples. 
In conclusion, in elderly patients with stable CAD, elevated sdLDL-C levels 
measured by an automated homogenous assay were strongly associated with CE 
recurrence independent of LDL-C. Secondly, decreased LDL-PD was significantly 
associated with incident CEs independent of LDL-C and sdLDL-C. Thirdly, of all the 
lipid biomarkers, only sdLDL-C was independently associated with CEs among patients 
treated with statins. Fourthly, a significant association of sdLDL-C and incident CEs 
was consistently observed all patient subpopulations including those with diabetes and 
hypertriglyceridemia, which are well-known high-risk populations. The results showed 
sdLDL-C to be a more effective secondary prevention biomarker than LDL-C to predict 
future CEs. A large cohort study is required to determine the appropriate target level of 
sdLDL-C. 
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Figure Legend 
Figure 1. The Kaplan–Meier event-free survival of patients stratified by the median 
sdLDL-C concentration (25 mg/dl): (A) All patients; (B) Patients treated with statins; 
(C) Diabetes patients. 
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Supplementary Table 1.  Cardiovascular events 
Supplementary Table 2.  Spearman’s correlation of LDL-C or sdLDL-C and 
patient characteristics 
 
  
Table 1. Baseline clinical characteristics  
 Whole 
(n=345) 
CE 
(n=96) 
non-CE 
(n=249) p 
Age, years 72.8 ± 5.4 72.9 ± 5.2 72.7 ± 5.5 0.597 
Body mass index, kg/m2 23.8 ± 3.1 24.5 ± 3.3 23.5 ± 3.0 0.018 
Prior MI, n (%) 205 (59.4) 56 (58.3) 149 (59.8) 0.446 
Prior PCI/CABG, n (%) 272 (78.8) 72 (75) 200 (80.3) 0.174 
Need for coronary revascularization at baseline 102 (29.6) 43 (44.8) 59 (23.7) <0.001 
Peripheral Artery Disease 
Risk factors 
31 (9.0%) 
 
15 (15.6%) 
 
16 (6.4%) 
 
0.011 
 
 Hypertension 
Diabetes mellitus 
Dyslipidemia 
Smoking (Current and Former) 
262 (75.9) 
115 (33.3) 
301 (87.2) 
267 (77.4) 
72 (75) 
48 (50) 
86 (89.6) 
78 (81.3) 
190 (76.3) 
67 (13.5) 
215 (86.4) 
189 (75.9) 
0.451 
<0.001 
0.269 
0.179 
Cardiovascular medication     
 Calcium Channel Blocker 
ACE inhibitors 
ARB 
Beta-blocker 
Antiplatelet 
Oral anti-diabetic drugs 
Insulin 
Statin 
Lipid-lowering except statin 
149 (43.2) 
191 (55.4) 
50 (14.5) 
102 (29.6) 
311 (90.4) 
94 (27.2) 
26 (7.5) 
208 (60.3) 
26 (7.5) 
50 (52.1) 
59 (61.5) 
8 (8.3) 
28 (29.2) 
89 (92.7) 
38 (39.6) 
13 (13.5) 
49 (51.0) 
7 (7.3) 
99 (39.8) 
132 (53.0) 
42 (16.9) 
74 (29.7) 
222 (89.5) 
56 (22.5) 
13 (5.2) 
159 (63.9) 
19 (7.6) 
0.026 
0.098 
0.028 
0.516 
0.283 
<0.001 
0.009 
0.02 
0.559 
Data are means ± SD or number (%). Risk factors and medications, including prior 
lipid-lowering drugs at baseline, were evaluated at the time of blood sampling. N/A = not 
available; ACE-I = angiotensin-converting enzyme inhibitor; ACS = acute coronary syndrome; 
ARB = angiotensin II type 1 receptor blocker; CABG = coronary artery bypass graft surgery; 
MI = myocardial infarction; PCI = percutaneous coronary intervention. 
  
Table 2. Laboratory findings in patients with and without CEs. 
 Whole 
(n=345) 
CE 
(n=96) 
non-CE 
(n=249) p 
LDL-C, mg/dL 100.5 ± 30.1 107.3 ± 30.0 97.9 ± 29.7 0.008 
sdLDL-C, mg/dL 28.2 ± 12.9 31.8 ± 15.1 26.9 ± 11.7 0.008 
lbLDL-C, mg/dL 72.2 ± 24.2 75.5 ± 25.3 71.0 ± 23.7 0.171 
LDL-PD, Å 256.2 ± 4.5 255.3 ± 4.9 256.5 ± 4.2 0.032 
Non-HDL-C, mg/dL  128.7 ± 34.0 137.7 ± 35.3 125.3 ± 32.9 0.003 
Triglycerides, mg/dL  123.1 ± 70.5 133.7 ± 87.6 119.0 ± 62.5 0.195 
HDL-C, mg/dL  46.6 ± 14.4 44.1 ± 12.7 47.5 ± 15.0 0.060 
LDL-C/HDL-C  2.4 ± 1.0 2.6 ± 1.0 2.3 ± 1.0 0.001 
sdLDL-C/LDL-C 0.28 ± 0.10 0.30 ± 0.12 0.28 ± 0.96 0.15 
ApoA1, mg/dL  124.9 ± 25.8 119.2 ± 23.1 127.0 ± 26.5 0.013 
ApoB, mg/dL  85.8 ± 21.0 91.0 ± 20.3 83.9 ± 21.1 0.004 
Lipoprotein(a), mg/dL  22.8 ± 24.7 25.0 ± 25.2 22.0 ± 24.5 0.296 
RLP-C, mg/dL  4.4 ± 3.0 4.8 ± 3.3 4.3 ± 2.9 0.04 
Glucose, mg/dL  114.1 ± 35.5 121.3 ± 45.6 111.3 ± 30.5 0.038 
HbA1c, % 6.3 ± 1.1 6.7 ± 1.5 6.1 ± 0.88 <0.001 
eGFR, mL/min/1.73 m2  62.4 ± 18.1 62.6 ± 20.4 62.3 ± 17.2 0.479 
BNP, pg/mL  105.1 ± 170.7 149.0 ± 254.0 87.7 ± 119.5 0.021 
hsCRP, mg/dL 0.40 ± 1.0 0.52 ± 1.4 0.35 ± 0.81 0.347 
Table 3. Age-adjusted hazard ratios (95% CI) for occurrence of major CEs 
 
variables  
Univariate model Multivariate model 
  Model 1 Model2 
LDL-C /10mg/dl 1.085 (1.017-1.157)* 1.174 (0.977-1.410) 1.022 (0.937-1.114) 
sdLDL-C /10mg/dl 1.256 (1.091-1.446)** 1.158 (0.903-1.486) 1.210 (1.003-1.459)* 
LDL-PD 0.945 (0.905–0.987)** 0.933 (0.882–0.986)* ー 
T-C /10mg/dl  1.054 (0.997-1.115) ー ー 
Non HDL-C /10mg/dl  1.085 (1.026-1.148)** 1.129 (0.910-1.401) ー 
LDL-C/HDL-C  1.340 (1.115–1.611)** 0.646 (0.313–1.355) ー 
Apolipoprotein A1 /10mg/dl  0.892 (0.820-0.971)** 0.839 (0.694-1.016) 0.897 (0.822-0.980)* 
Apolipoprotein B /10mg/dl  1.134 (1.034-1.243)** 0.782 (0.531-1.150) ー 
RLP-C  1.035 (0.980–1.093) ー ー 
Glucose  1.006 (1.001–1.011)* 0.996 (0.989–1.003) ー 
HbA1c 1.407 (1.237–1.600)*** 1.420 (1.143–1.765)** ー 
BNP  1.001 (1.000–1.002)** 1.001 (1.000–1.002) ー 
T-C = total cholesterol 
*p<0.05, **p<0.01, ***p<0.001 
Table 4. Univariate age-adjusted hazard ratios (95% CI) for occurrence of major 
CEs in patient subpopulations 
 
 Statin users 
(n=208) 
Hypertriglyceridemia 
(n=80) 
Diabetes 
(n=115) 
Non-diabetes 
(N=230) 
LDL-C /10mg/dL 1.062 (0.957-1.177) 1.089 (0.977-1.214) 1.103 (1.006-1.208)* 1.078 (0.985-1.180) 
sdLDL-C /10mg/dL 1.252 (1.017-1.540)* 1.376 (1.070-1.770)* 1.219 (1.018-1.460)* 1.257 (1.019-1.551)* 
sdLDL-C/LDL-C 6.111 (0.531–70.294) 5.453 (0.294–101.292) 3.455 (0.299–39.923) 5.888 (0.394-88.098) 
LDL-PD, 0.956 (0.901–1.015) 0.966 (0.884–1.056) 0.960 (0.897–1.028) 0.934 (0.883–0.989)* 
lbLDL-C /10mg/dL 1.016 (0.893-1.156) 1.037 (0.913-1.176) 1.088 (0.968-1.223) 1.058 (0.943-1.186) 
Triglycerides 
/10mg/dL 1.005 (0.965-1.048) 1.029 (0.991-1.068) 1.003 (0.974-1.034) 1.044 (0.998-1.092) 
T-C/10mg/dL 1.043 (0.958-1.136) 1.060 (0.968-1.162) 1.047 (0.972-1.128) 1.058 (0.977-1.146) 
HDL-C /10mg/dL 0.932 (0.745-1.167) 0.877 (0.635-1.211) 0.895 (0.733-1.093) 0.842 (0.667-1.063) 
Non-HDL-C 
/10mg/dL 1.060 (0.971-1.0157) 1.088 (0.987-1.200) 1.079 (0.996-1.169) 1.082 (1.001-1.170)* 
LDL-C/HDL-C  1.281 (0.909–1.805) 1.222 (0.860–1.737) 1.394 (1.018–1.910)* 1.325 (1.037–1.692)* 
Apo A1 /10mg/dL  0.919 (0.813-1.039) 0.886 (0.763-1.028) 0.894 (0.788-1.015) 0.907 (0.807-1.018) 
Apo B /10mg/dL  1.079 (0.933-1.247) 1.104 (0.935-1.305) 1.157 (1.011-1.324)* 1.126 (0.993-1.277) 
Lipoprotein(a) 1.004 (0.995–1.013) 1.023 (1.008–1.039)** 1.012 (1.000–1.025) 1.004 (0.994–1.015) 
RLP-C  0.999 (0.899–1.111) 1.005 (0.918–1.100) 1.000 (0.936–1.068) 1.089 (0.940–1.261) 
Glucose  1.005 (0.997–1.013) 1.000 (0.991–1.009) 1.002 (0.996–1.008) 0.995 (0.975–1.015) 
HbA1c 1.574 (1.264–1.960)*** 1.186 (0.916–1.534) 1.304 (1.088–1.563)** 1.157 (0.654–2.046) 
eGFR  0.999 (0.981–1.018) 0.984 (0.962–1.007) 1.003 (0.988–1.018) 1.007 (0.989–1.025) 
hs-CRP 0.424 (0.113–1.588) 0.892 (0.418–1.904) 0.949 (0.635–1.408) 1.202 (1.016–1.422)* 
BNP  1.001 (0.999–1.003) 1.001 (0.999–1.003) 1.001 (1.000–1.002)** 1.001 (0.999–1.003) 
 
*p<0.05, **p<0.01, ***p<0.001 
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Supplementary Table 1.  Cardiovascular events 
 
Cardiovascular events Number 
Fatal events 11 
 Acute coronary syndrome 
Congestive heart failure 
Other cardiovascular death 
1 
6 
4 
Nonfatal events 85 
 Acute coronary syndrome 
Any revascularization (endovascular treatment) 
Congestive heart failure 
Stroke 
11 
46 (3) 
11 
14 
 2 
Supplementary Table 2. Spearman’s correlation of LDL-C or sdLDL-C and patient 
characterisrics 
 LDL-C sdLDL-C 
 Rho p Rho p 
age −0.003 0.956 −0.091 0.092 
BMI 0.092 0.092 0.155 0.004 
LDL-PD −0.119 0.029 −0.376 <0.001 
Large LDL-C 0.902 <0.001 0.314 <0.001 
Non-HDL-C  0.905 <0.001 0.758 <0.001 
HDL-C  −0.086 0.11 −0.16 0.003 
Triglycerides  0.165 0.002 0.452 <0.001 
Apolipoprotein A1  −0.175 0.001 −0.078 0.158 
Apolipoprotein B  0.886 <0.001 0.796 <0.001 
Lipoprotein(a)  0.134 0.018 −0.025 0.661 
RLP-C  0.335 <0.001 0.516 <0.001 
Glucose  −0.117 0.03 0.024 0.66 
HbA1c −0.051 0.341 0.036 0.507 
eGFR  0.036 0.499 0.098 0.069 
hsCRP 0.156 0.004 0.124 0.022 
BNP  0.011 0.85 −0.072 0.196 
	  
